TRDA - Entrada Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart

TRDA is currently covered by 2 analysts with an average price target of $13. This is a potential upside of $8.65 (198.85%) from yesterday's end of day stock price of $4.35.

Entrada Therapeutics's activity chart (see below) currently has 32 price targets and 33 ratings on display. The stock rating distribution of TRDA is 100% BUY.

Stock Analyst Price Targets - Review

Analysts' price targets on this stock were met 24.21% of the time, taking 84 days on average.

Highest price target for TRDA is $13, Lowest price target is $13, average price target is $13.

Most recent stock forecast was given by DEBJIT CHATTOPADHYAY from GUGGENHEIM. First documented stock forecast 23-Nov-2021.

Currently out of the existing stock ratings of TRDA, 5 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 11-Feb-2026

$13

$8.65 (198.85%)

$17

3 days ago
(18-Nov-2026)

Buy Since 03-Apr-2023

$20

6 months 13 days ago
(08-May-2026)

4/14 (28.57%)

$8.96 (81.16%)

126

Buy Since 25-Apr-2023

$17

$20

1 years 3 months 14 days ago
(07-Aug-2025)

1/6 (16.67%)

$11.7 (220.75%)

371

Buy Since 04-Jan-2024

$30

$22

1 years 7 months 28 days ago
(24-Mar-2025)

0/2 (0%)

$19.2 (177.78%)

Buy Since 26-Aug-2024

$30

$28

1 years 8 months 24 days ago
(28-Feb-2025)

0/3 (0%)

$18.06 (151.26%)

Show more analysts

Please expand the browser size to see the chart

What is TRDA (Entrada Therapeutics) average time for price targets to be met?

On average it took 84 days for the stock forecasts to be reached, with an average price target met ratio of 24.21%.

Which analyst most recently updated their price target on TRDA (Entrada Therapeutics)?

Debjit Chattopadhyay

Which analyst has the lowest performance score on TRDA (Entrada Therapeutics) with a proven track record?

DEBJIT CHATTOPADHYAY

Which analyst has the most public recommendations on TRDA (Entrada Therapeutics)?

Debjit Chattopadhyay works at GUGGENHEIM and has 4 price targets and 3 ratings on TRDA

Which analyst is the currently most bullish on TRDA (Entrada Therapeutics)?

Francois Brisebois with the highest potential upside of $25.65

Which analyst is the currently most reserved on TRDA (Entrada Therapeutics)?

Chris Shibutani with the lowest potential downside of -$0
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?